Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）
- Generic Name
- Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）
- Indication
用于：1.恶性肿瘤、白血病化、放疗引起的白血病减少及其并发的感染；
2.造血干/祖细胞移植后髓系造血功能受抑及延迟植活与移植排斥；
3.与rhG-CSF等造血生长因子联合或单独应用于外周血造血干/祖细胞移植前的干/祖细胞动员；
4.再生障碍性贫血等骨髓衰竭性疾患及各种严重感染并发的中性粒细胞减少；
5.也可用于艾滋病本身、或因药物治疗所致的中性粒细胞减少。
A Comparison of Dendritic Cell Content and T-Cell Phenotype Between Granulocyte Colony-Stimulating Factor (G-CSF) or G-CSF + Granulocyte Macrophage (GM)-CSF
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2012-09-14
- Lead Sponsor
- Emory University
- Target Recruit Count
- 50
- Registration Number
- NCT00208949
- Locations
- 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens
- Conditions
- Malignant Melanoma
- Interventions
- Biological: mRNA coding for melanoma associated antigens
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 31
- Registration Number
- NCT00204516
- Locations
- 🇩🇪
Department of Dermatology, University of Tuebingen, Tuebingen, Germany
A Randomized Trial of GM-CSF in Patients With ALI/ARDS
- Conditions
- Respiratory Distress Syndrome, Adult
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2015-12-29
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 132
- Registration Number
- NCT00201409
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
🇺🇸University of Colorado Health Sciences Center, Denver, Colorado, United States
Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients
- Conditions
- Malignant Melanoma
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2007-04-19
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 20
- Registration Number
- NCT00204607
- Locations
- 🇩🇪
Department of Dermatology, University of Tübingen, Tübingen, Germany
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2004-05-27
- Last Posted Date
- 2015-11-23
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 668
- Registration Number
- NCT00083551
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States
Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP
- Conditions
- HIV Infections
- First Posted Date
- 2004-01-14
- Last Posted Date
- 2021-10-14
- Target Recruit Count
- 96
- Registration Number
- NCT00076037
- Locations
- 🇺🇸
Saint Louis Univ. School of Medicine, HVTU, Saint Louis, Missouri, United States
🇺🇸FHCRC/UW Vaccine CRS, Seattle, Washington, United States
🇺🇸Alabama Vaccine CRS, Birmingham, Alabama, United States
Sequential Vaccinations in Prostate Cancer Patients
- Conditions
- Prostatic Neoplasms
- Interventions
- Drug: Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM)Drug: Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM)Drug: Recombinant Fowlpox-GM-CSF
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 32
- Registration Number
- NCT00060528
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
GM-CSF in Patients With Pulmonary Alveolar Proteinosis
- Conditions
- Pulmonary Alveolar Proteinosis
- First Posted Date
- 2002-01-31
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 48
- Registration Number
- NCT00030056
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸The University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸National Jewish Medical Center, Denver, Colorado, United States
A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas
- Conditions
- Ewing's SarcomaRhabdomyosarcoma
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00001564
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
- Conditions
- B Cell LymphomaFollicular LymphomaLymphoma
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00001512
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.